Benchmark Holdings PLC's (LON:BMK) Trond Williksen and Septima Maguire join Proactive London after receiving marketing authorisation from the Norwegian Medicines Agency (NoMA) for its pioneering treatment for sea lice in salmon.
EctosanVet (BMK08) treats one of the biggest biological challenges in salmon farming - sea lice. This problem comes at an estimated cost to producers of more than US$1bn annually, and US$600mln in Norway alone.
Ectosan Vet will be the first sea lice veterinary medicinal treatment to be introduced to the Norwegian salmon market in over a decade.
Ten years in the making, Trond says the regulatory path has been 'extensive'.